Ginsenoside Rg5 alleviates allergic rhinitis in rats by modulating nasal microbiota by inhibiting JAK2/STAT3/BCL-2 and MAPK signaling.

Save

Background

Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of nasal mucosa mediated by IgE and driven by type 2 immune response. Ginsenoside Rg5 (Rg5) is a bioactive compound derived from ginseng, but its effect on AR is unknown.

Objective

This study investigated the therapeutic potential of Rg5 in toluene diisocyanate (TDI)-induced AR and explored its potential mechanism involving JAK2/SATAT3/BCL-2 and MAPK signaling pathways as well as nasal microbiota regulation.

Methods

AR model was established by TDI sensitization and different doses of Rg5 were administered to assess symptom scores, IgE, His and cytokine levels. Nasal mucosal tissues and lung tissues were analyzed histopathologically for key proteins in the JAK2/STAT3/BCL-2 and MAPK pathways in the nasal mucosa. Nasal microbiota composition was assessed using 16S rRNA sequencing and signaling pathway correlation analysis was performed.

Results

Rg5 significantly reduces IgE, His, and pro-inflammatory factors, increases anti-inflammatory factors, mitigates damage to the nasal mucosa and lung tissues, thereby alleviates nasal symptoms. It suppresses the activation of JAK2/STAT3 and MAPK pathways and upregulates BCL-2 expression. It also increases the abundance of Actinobacteria and Acidobacteria, decreases that of Bacteroidetes and Desulfobacteria, and restores the diversity of nasal microbiota.

Rg5 ameliorates AR symptoms by enriching beneficial bacteria (e.g., Campylobacterota, Patescibacteria, and Acidobacteriota), regulating cytokine levels, and synergistically modulating the JAK2/STAT3/BCL-2 and MAPK pathways.

Conclusion

Ginsenoside Rg5 acts synergistically through the JAK2/STAT3/BCL-2 and MAPK signaling pathways while restoring nasal microbiota homeostasis and attenuating TDI-induced AR symptoms, highlighting its potential as a novel therapeutic agent for AR.

Introduction

Allergic rhinitis (AR) is a chronic IgE-mediated type 2 immune response‒driven inflammation of the nasal mucosa, characterized by sudden sneezing, rhinorrhea, nasal pruritus, and nasal congestion. These symptoms substantially impair patients' daily activities and work efficiency [1]. Driven by environmental pollution and lifestyle changes, the global prevalence of AR continues to rise, representing a considerable public health concern.

AR affects approximately 10–30 % of the global population, with a marked increase in prevalence among children and adolescents [2]. Current standard treatments, including allergen avoidance, antihistamines, intranasal corticosteroids, and immunotherapy, are constrained by side effects, prolonged treatment duration, and high costs [3], underscoring the urgent need for safer, more effective, and cost-efficient alternatives.

The pathogenesis of AR involves complex signaling pathways. STAT3, a transcription factor that regulates allergic responses and contributes to cell function, has emerged as a target for anti-allergic therapies [4]. STAT3 is activated by JAK kinases and extracellular signal-regulated kinases (ERK), leading to phosphorylation, dimerization, and nuclear translocation, where it modulates target genes such as RORγt, BCL-2, and CCL2 to regulate allergic reactions.

However, its regulatory role in AR remains elusive [5]. The MAPK signaling pathway comprises components including ERK, c-Jun N-terminal kinase (JNK), and p38 [6]. Inhibition of the ERK pathway blocks activation of the interleukin-5 receptor (IL-5R) and eosinophil chemotactic factor receptor in eosinophils, thereby alleviating inflammatory responses in allergic asthma.

Moreover, the JNK and p38 pathways are frequently activated in response to cytokine signaling or stress-induced environments. The MAPK signaling pathway mediates phosphorylation of inflammation-associated transcription factors, thereby promoting cytokine and chemokine synthesis. Although its role in allergic asthma has been established, its impact on toluene diisocyanate (TDI)-induced AR inflammation remains uncharacterized.

Microbiome dysbiosis also plays a pivotal role in AR, exacerbating inflammatory responses by disrupting immunoregulatory mechanisms [7]. The gut microbiome contributes to maintaining equilibrium between effector T cells (e.g., Th1, Th2, and Th17) and regulatory T cells, thereby alleviating allergic symptoms [8]. Certain genera within the phylum Firmicutes produce butyrate, which helps alleviate AR symptoms by maintaining immune homeostasis, particularly between Th2 and Th17 cells [9].

However, research investigating the role of nasal microbiota dysbiosis in AR remains relatively scarce compared with the extensive literature on the gut microbiota.

Ginseng, a traditional Chinese medicinal herb, has demonstrated broad therapeutic potential in allergic airway diseases [10]. Ginsenoside Rg5 (Rg5), a rare ginsenoside found in ginseng, exhibits immunomodulatory, anti-inflammatory, and anti-cancer effects [11,12]. Rg5 suppresses IgE–antigen complex–induced passive cutaneous allergic reactions in mice, suggesting its potential for improving allergic diseases [13].

However, the mechanisms by which Rg5 influences AR in vivo, particularly its effects on signaling pathways and the nasal microbiota, remain poorly understood.

In this study, we aimed to investigate the effects of Rg5 on AR in rats. We assessed behavioral alterations; levels of IgE, histamine (His), and cytokines; and histopathological changes in the nasal mucosa and lung tissues. We further explored the involvement of the JAK2/STAT3/BCL-2 and MAPK signaling pathways while analyzing the composition and diversity of the nasal microbiota, correlating these findings with cytokines, IgE, histamine, and signaling pathways.

Overall, this study seeks to elucidate the mechanisms underlying the therapeutic effects of Rg5 in AR, providing novel insights for the development of safer and more effective therapeutic strategies.

Materials and methods

Reagents and materials

Ginsenoside Rg5 (purity >95 %; Cat No: 186763-78-0) was purchased from ChangChun Yuanda Biotechnology Co., Ltd. (Shanghai, China). Loratadine (Lor) was acquired from Beijing Shuanglu Pharmaceutical Co., Ltd.

(Cat No. H20060157). TDI was purchased from Shanghai Macklin Biochemical Technology Co., Ltd.

(Cat No: T830062-25g). Olive oil (Cat No: O815210) was acquired from Shanghai McLean Biochemical Technology Co., Ltd. All remaining reagents were of analytical grade.

Animals

The animal experimental protocol was approved by the Animal Management and Ethics Committee affiliated with the Institute of Zoology and Botany at the Chinese Academy of Agricultural Sciences (ISAPSAEC-2022-66). To induce an AR model, rats were selected because their nasal epithelial structure is similar to that of humans, and they provide a cost-effective alternative for disease research. The experimental animals were SPF-grade male Sprague–Dawley rats (180–200 g; identification number: SCXK [Liao] 2020-0001) fed a standard diet (Liaoning Changsheng Biotechnology Co., Ltd., China).

Drinking water was sterilized through high-pressure treatment. A total of 42 rats were housed in SPF animal rooms maintained at 20–22 °C and 50–55 % relative humidity under a 12 h light/12 h dark cycle. Before the experiment, all rats were housed in an isolation room for one week.

Water and feed were provided ad libitum.

The AR model was established based on the method of Shahriar et al. (2009), which reliably induces allergic reactions [14]. Rats in the control group, AR group, and TDI-induced AR group were orally administered Lor at a dose of 1.028 mg/kg.

Additionally, rats in the TDI-induced AR group were orally administered Rg5 at doses of 12.5 mg/kg (Rg5-L), 25 mg/kg (Rg5-M), and 50 mg/kg (Rg5-H).

TDI-induced AR rat model and treatment

After adaptive feeding, all rats except those in the control group were sensitized by intranasal administration of 10 μL of 10 % TDI solution (TDI dissolved in olive oil) into per nasal cavity once daily for 7 consecutive days. Rats in the control cohort received 10 μL of olive oil per nasal cavity, serving as a substitute for the TDI intervention. From days 8–21, all rats except those in the control group received intranasal administration of 10 % TDI solution into each nasal cavity once every two days to maintain sensitization, for a total of seven administrations.

Rats in the control group received a 10 μL dose of olive oil in each nasal cavity as a substitute for TDI. From days 8–21, rats in the Rg5 and Lor groups received their respective oral doses once daily, whereas rats in the AR and control groups received physiological saline only. All treatments, including drug and saline administration, were administered 30 min before nasal stimulation each day for a total of 14 days.

Nasal symptom scoring and basic indicator measurement

Nasal symptom scoring was performed on days 7 and 22 of the study. After nasal stimulation with the TDI solution, rats were allowed a 30-min adaptation period, after which data were recorded by blinded observers. During this period, the number of scratching events, sneezes, and episodes of rhinorrhea were recorded as described previously [15].

After scoring the nasal symptoms, the rats were weighed and anesthetized by intraperitoneal injection of pentobarbital sodium. A polyethylene catheter (1 mm diameter) was carefully inserted into the nasopharyngeal space, and 8 mL of nasal lavage fluid was collected. Immediately thereafter, intracardiac blood samples were collected, and nasal tissue, spleen, liver, lungs, and thymus were dissected and weighed promptly.

The blood samples were centrifuged at 3000 rpm for 10 min, and the resulting supernatant was collected. All tissue samples and supernatants were stored at −80 °C for subsequent analysis.

ELISA detection

Collected serum samples were used to quantify interleukin (IL)-2, IL-4, IL-6, IL-10, IgE, and His levels using respective ELISA kits. The following antibodies were used: IgE (ml003022V), His (YJ002986), IL-6 (YJ102828), IL-4 (YJ102825), IL-10 (YJ002813), and IL-2 (YJ102822). All reagents were purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd.

(Shanghai, China).

Histopathological analysis

Nasal and lung tissue specimens were collected for histopathological evaluation. Samples were fixed in 10 % formalin solution for 48 h, after which nasal tissues were decalcified and embedded in paraffin blocks according to the standard bone tissue procedures, whereas lung tissues were directly embedded in paraffin. All tissue specimens were sectioned into 4 μm-thick slices, stained using hematoxylin and eosin (H&E; E607318-0200, BBI), and observed under a microscope (BX53; Olympus, Tokyo, Japan), with images acquired under the same intensity.

Network pharmacology analysis

The SMILES structure of Rg5 was retrieved from PubChem and entered into SwissTarget Prediction to predict potential targets. Therapeutic targets associated with AR were obtained from GeneCards and OMIM databases and then standardized using UniProt. Overlapping targets between Rg5-predicted and AR-related genes were identified.

“Homo sapiens” was selected as the reference species, and the overlapping genes were submitted to the STRING database to construct a protein–protein interaction (PPI) network. The network was visualized using Cytoscape 3.7.2. Functional enrichment analyses, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG), were conducted using the clusterProfiler package in R.

The Pathview package was used to visualize pathway enrichment. All data were collected in September 2024.

Western blot analysis

A 10 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was prepared, and 40 μg of protein was loaded per lane. The separated proteins were then transferred to a polyvinylidene fluoride (PVDF) membrane, which was subsequently blocked in a blocking solution (5 % skim milk) for 60 min. The membrane was washed with a phosphate-buffered saline solution supplemented with Tween 20 (PBST) buffer and incubated with the primary antibody at 4 °C overnight.

Thereafter, the membrane was incubated with species-specific secondary antibodies at room temperature for 60 min. Protein bands were visualized using enhanced chemiluminescence (ECL). ImageJ software (National Institutes of Health, Bethesda, MD) was used to analyze the grayscale values. β-actin and glyceraldehyde-3-phosphate dehydrogenase (GADPH) were used as controls.

Relative protein expression was calculated as the ratio target protein to the corresponding internal control, and differences between groups were compared.

The following antibodies have been used: anti-p-p38 (1:500; #sc-7973), anti-p38 (1:500; #sc-7972), anti-p-JNK (1:500; #sc-7345), anti-JNK (1:500; #sc-6254), anti-P-ERK (1:500; #sc-7383), anti-ERK (1:500; #sc-1647), and anti-β-actin (1:500; #T0022) were obtained from Santa Cruz Biotechnology Co., Ltd., USA. Anti-p-JAK2 (1:1000; ab32101), anti-JAK2 (1:1000; ab108596), anti-p-STAT3 (1:1000; ab32143), anti-STAT3 (1:1000; ab68153), anti-BCL-2 (1:1000; ab182858), and anti-GADPH (1:1000; ab8245) were purchased from Abcam Corporation (United States).

Molecular docking verification

The structure of ginsenoside Rg5 was downloaded from PubChem and imported into ChemBio3D 14.0. The conformation was adjusted, energy was optimized, and the structure was saved in the mol2 format. It was then processed with AutoDockTools 1.5.6 to convert it into the pdbqt format.

The three-dimensional (3D) structure of the target protein was obtained from the Protein Data Bank, and water molecules and organic ligands were removed using Notepad2. The protein structure was further processed in AutoDockTools through dehydration, hydrogenation, and other modifications before being saved in the pdbqt format. Docking simulations were performed using AutoDockVina, and the results were visualized in PyMOL.

Finally, the three-dimensional interaction results were analyzed using Discovery Studio 2020.

Microbiome analysis

Following the final administration, all rats were fasted for 3 h, after which sterile nasal lavage fluid (for 16S rRNA sequencing) was collected and stored at −80 °C. Approximately 8 mL of nasal lavage fluid from each rat was stored on dry ice and sent to Beijing Novogene Technology Co., Ltd. for 16S rRNA sequencing of the nasal microbiota. Microbial DNA was extracted from the samples using a DNA extraction kit and quantified using an ultramicro spectrophotometer.

DNA integrity, purity, fragment size, and concentration were quantitatively detected using agarose gel electrophoresis. The V3–V4 hypervariable region of the 16S rRNA gene was used to design primers for PCR amplification.

Statistical analysis

Data are presented as mean ± standard error of the mean. Statistical analyses were conducted using GraphPad Prism 10.0 (GraphPad Software, Boston, MA, USA). One-way analysis of variance was used to assess the differences between groups, with statistical significance defined as P < 0.05.

Results

Effect of Rg5 on nasal symptoms and basic indicators in TDI-induced AR rats

The experimental protocol is shown in Fig. 1A. To evaluate the effect of Rg5 on nasal symptoms and basic physiological parameters, AR rats were assessed for nasal manifestations, including swelling, sneezing, nose scratching, and rhinorrhea.

After 3 weeks of intranasal stimulation with TDI solution, rats in the AR group exhibited a marked increase in the frequency of nose rubbing and sneezing, along with notable nasal discharge and swelling, compared with the control group (Fig. 1B–D, E). Compared with rats in the AR group, rats treated with Lor and various doses of Rg5 (low [Rg5-L], medium [Rg5-M], and high [Rg5-H]) demonstrated a significant reduction in sneezing and nose rubbing, as well as alleviation of nasal discharge and swelling.

Notably, the Rg5-H group achieved greater symptom relief than the Lor group. Organ indices were calculated by monitoring the body weight and measuring the weights of the liver, spleen, and thymus. No significant differences were observed in body weight, spleen index, or thymus index among the groups.

However, the AR group demonstrated a significant reduction in liver index compared with the control group. Compared with the AR group, the Lor and Rg5 groups showed a notable recovery of the liver index, with the Lor and Rg5-H groups recovering to levels of the control group (Fig. 1C–F–H).Fig.

1The effect of Rg5 on nasal symptoms and basic indicators in TDI induced AR rats. (A) Timeline of AR rat model. (B) Nasal symptoms in rats on the last day.

(C) Body weight. (D) The frequency of sneezing. (E) The frequency of rubbing.

(F) liver index. (G) Thymus index. (H) Spleen index.

Data are shown as mean ± SEM. ##P < 0.01 vs. control group, ###P < 0.001 vs. control group, ∗P < 0.05 vs. AR group, ∗∗P < 0.01 vs. AR group, ∗∗∗P < 0.001 vs.

AR group.Fig. 1

Effect of Rg5 on cytokines in TDI-induced AR rats

IgE and His are key immune and pathophysiological markers for AR. As shown in Fig. 2A and B, compared with the control group, the AR group exhibited significantly elevated levels of IgE and His.

Treatment with Rg5 or Lor resulted in significant reductions in both markers, with the Rg5-H group exhibiting the most pronounced effect. As shown in Fig. 2C–F, compared with the control group, the AR group exhibited significantly increased levels of all four examined cytokines.

Compared with the AR group, the Lor- and Rg5-treated groups (Rg5-L, Rg5-M, and Rg5-H) showed a significant reduction in cytokine levels, with the greatest reduction observed in the Rg5-H group.Fig. 2The effect of Rg5 on TDI-induced AR rat cytokine and histopathology. (A) The level of IgE.

(B) The level of His. (C) The level of IL-6. (D) The level of IL-4.

(E) The level of IL-2. (F) The level of IL-10. (G) Histopathological changes in the nasal mucosa.

(H) Histopathological changes in the lungs. Data are shown as mean ± SEM. ##P < 0.01 vs. control group, ###P < 0.001 vs. control group, ∗P < 0.05 vs. AR group, ∗∗P < 0.01 vs.

AR group, ∗∗∗P < 0.001 vs. AR group.Fig. 2

Pathological effects of Rg5 on the nasal mucosa and lung tissue of TDI-induced AR rats

As shown in Fig. 2G, epithelial cells and cilia in the nasal mucosa of control rats were regularly arranged and structurally intact, with no discernible inflammatory cell infiltration. In the AR group, the nasal mucosa displayed pronounced disruption of epithelial continuity, accompanied by basal layer hyperplasia, vasodilatation, and marked inflammatory pathology.

Compared with the AR group, the treated groups exhibited improved nasal mucosal epithelial architecture, with better preservation of structural integrity. Cellular arrangement appeared more orderly, vasodilatation was reduced, and both glandular hyperplasia and inflammatory responses were markedly alleviated. As shown in Fig.

2H, the lung tissue in control rats was structurally intact, whereas rats in the AR group exhibited alveolar lumen rupture, marked thickening of the alveolar septa, and blood seepage. Rats in all Rg5-treated groups showed varying degrees of recovery, with reduced inflammatory infiltration, congestion, and edema, as well as improvements in alveolar damage, including decreased alveolar destruction, expansion, and fusion.

Target collection, PPI network construction, and analysis

Using the SwissTargetPrediction platform, 54 distinct potential molecular targets of Rg5 were identified after removing duplicates. AR-related targets were retrieved from relevant databases. After data integration and the removal of redundant entries and low-confidence targets, a curated database of 2671 AR-related targets was established.

By intersecting the Rg5-related and AR-related target datasets, 54 overlapping targets were identified as potential therapeutic candidates (Fig. 3B). These targets were then imported into the STRING 11.0 database to construct a PPI network (Fig.

3C), which was further analyzed and visualized using Cytoscape. In the resulting network, node size was proportional to degree value, indicating the relative importance of each protein within the network. The ten most central nodes identified—STAT3, ICAM1, EGFR, MMP9, IL2, MMP2, KDR, FGF2, MTOR, and BCL2L1—were considered key therapeutic targets for Rg5 in the context of AR.Fig.

3Network pharmacology prediction, molecular docking, and Rg5 improve AR symptoms by inhibiting the JAK2/STAT3/BCL-2 and MAPK pathways. (A) The interaction network between Rg5 and AR target compounds (note: blue nodes represent target genes, green nodes represent medicinal herbs). (B) The Venn diagram of drugs and diseases.

(C) The PPI network of Rg5 against AR. (D) GO chart. (E) The top 20 KEGG signaling pathways related to the anti AR effect of Rg5.

(F) The binding modes of Rg5 with different proteins. (a–f) The binding patterns between Rg5 and STAT3, JAK2, BCL-2, P38, JNK, and ERK. (G) Binding energy of active components and core targets (KJ/mol).

(H) Western blot image of MAPK pathway. (I) Western blot images of JAK2/STAT3/BCL-2 pathway. (J) relative expression of P-P38/P38.

(K) relative expression of P-ERK/ERK. (L) relative expression of P-JNK/JNK. (M) relative expression of BCL-2/β-actin.

(N) relative expression of P-JAK2/JAK2. (O) elative expression of P-STAT3/STAT3. β-actin and GADPH was used as the internal control. Data are shown as mean ± SEM. ; ##P < 0.01 vs. control group, ###P < 0.001 vs. control group, ∗P < 0.05 vs.

AR group, ∗∗P < 0.01 vs. AR group, ∗∗∗P < 0.001 vs. AR group.Fig.

3

GO and KEGG pathway enrichment analyses

The top 10 enriched terms for biological processes (BP), molecular functions (MF), and cellular components (CC) are visualized in the graphs (Fig. 3D). Key BP terms included cell chemotaxis, positive regulation of MAP kinase activity, and positive regulation of protein serine/threonine kinase activity, among others.

For MF, predominant enriched terms included serine-type endopeptidase activity, serine-type peptidase activity, and serine hydrolase activity, whereas CC terms were primarily enriched in collagen-containing extracellular matrix, membrane rafts, membrane microdomains, and membrane regions. In addition, the top 20 signaling pathways identified in the KEGG analysis are detailed in Fig. 3E, providing plausible mechanistic insights.

Molecular docking

Molecular docking experiments were performed using AutoDockTools to evaluate the affinity of Rg5 to the potential targets p38, ERK, JNK, JAK2, STAT3, and BCL-2, yielding six docking results. Lower binding energy indicated a higher affinity of the component for the target. The binding energies of all six target proteins were below −7.1 (Fig.

3G), suggesting favorable binding of Rg5 to these targets. The docking poses were further visualized using PyMOL, as shown in Fig. 3F.

Effect of Rg5 on JAK2/STAT3/BCL-2 and MAPK pathways

Based on the network pharmacology analysis, the MAPK signaling pathway was identified as a key regulatory pathway, with STAT3, JAK2, and BCL-2 among the most enriched targets in the PPI network. Experimental validation confirmed that TDI exposure led to a marked increase in the phosphorylation of p38, JNK, and ERK in nasal mucosal tissue. In contrast, Rg5 treatment markedly reduced phosphorylation levels of these MAPK components, with the most pronounced inhibition observed in the Rg5-H group (Fig.

3H–J–L). To evaluate the impact of Rg5 on the JAK2/STAT3 signaling pathway, we assessed the expression and phosphorylation status of JAK2 and STAT3, along with BCL-2 protein levels. TDI exposure markedly increased the phosphorylation of JAK2 and STAT3 while decreasing BCL-2 expression.

Conversely, Rg5 significantly reduced the expression of p-STAT3 and JAK2 and improved the expression of BCL-2 (Fig. 3I–M–O). Accordingly, Rg5 may alleviate allergic inflammation and AR symptoms by suppressing the JAK2/STAT3/BCL-2 and MAPK signaling cascades, with the Rg5-H group exhibiting the strongest therapeutic effect.

Effect of Rg5 on the composition and diversity of nasal microbiota induced by TDI in AR rats

Emerging evidence suggests that dysbiosis is strongly associated with the development of AR. Accordingly, we conducted 16S rRNA gene sequencing on nasal lavage fluid samples to evaluate the potential impact of Rg5 on nasal microbiome composition in AR model rats. At the current sequencing depth, the sample sequencing data were sufficient to capture microbial diversity within each group, validating the use of these samples for subsequent analysis (Fig.

4A). Microbial richness, assessed using the Chao1 index, was significantly lower in the control group than in the AR, Lor, and Rg5-treated groups. Notably, the AR group exhibited the highest microbial richness among all experimental cohorts (Fig.

4B). Shannon and Simpson indices were used to further evaluate microbial diversity. Compared with the control group, the AR group exhibited significantly elevated values for both indices, indicating enhanced microbial diversity during AR.

In contrast, oral administration of Rg5 and Lor significantly restored nasal microbiota diversity in AR rats. Following treatment with Lor and different doses of Rg5, the Simpson index in the Lor- and Rg5-L-treated groups gradually returned to levels comparable to those of the control group; the Shannon index in the Rg5-M group also normalized to match control group values (Fig. 4C and D).

Principal coordinate analysis revealed distinct clustering of microbial community structures across the groups, indicating good within-group consistency. However, Rg5 treatment did not result in significant changes in β-diversity (Fig. 4E).

Collectively, these findings suggest that Rg5 can modulate nasal microbiota composition in AR rats. At the phylum level, the AR group showed a higher relative abundance of Firmicutes, Bacteroidetes, Desulfomycetes, and Fusobacteria, along with a lower relative abundance of Proteobacteria, Cyanobacteria, Actinobacteria, Acidobacteria, and Patellaceae. Following Rg5 treatment, the relative abundance of Firmicutes, Cyanobacteria, Clostridium, Actinobacteria, Acidobacteria, and Patellaceae increased, whereas that of Proteobacteria, Bacteroidetes, and Desulfomycetes decreased.

Notably, Rg5 significantly increased the relative abundance of Cyanobacteria and Actinobacteria, while significantly decreasing that of Bacteroidetes and Desulfomycetes (Fig. 5A–H). Fig.

5A presents a heatmap showing differences in the overall abundance of certain genera in different populations.Fig. 4The effect of Rg5 on the composition and diversity of nasal microbiota induced by TDI in AR rats. (A) Alpha diversity analysis of intestinal flora in rats.

(B) α-diversity of chao1. (C) α-diversity of Simpson. (D) α-diversity of Shannon.

(E) β-diversity of PCoA. Data are shown as mean ± SEM. ###P < 0.001 vs. control group, ∗P < 0.05 vs. AR group, ∗∗P < 0.01 vs.

AR group, ∗∗∗P < 0.001 vs. AR group,&P < 0.05 vs. Lor group.Fig.

4Fig. 5The effect of Rg5 on the composition of nasal microbiota at the phylum level in AR rats (A) Species abundance heat map at the phylum level. (B) The relative abundance of nasal microbiota at the phylum level.

(C–H) Relative abundance of Desulfobacteria, Cyanobacteria, Bacteroidetes, Acidobacteria, Patellaceae, and Actinobacteria. Data are shown as mean ± SEM. ##P < 0.01 vs. control group, ###P < 0.001 vs. control group, ∗P < 0.05 vs. AR group, ∗∗P < 0.01 vs.

AR group, ∗∗∗P < 0.001 vs. AR group.Fig. 5

Linear discriminant analysis effect size (LEfSe) analysis

LEfSe analysis was performed to assess differences in microbial community abundance. A linear discriminant analysis threshold of ≥4 was applied to identify significantly differential microbial markers between groups, thereby revealing group-specific microbial characteristics. In total, 55 microbial taxa showed statistically significant differences across the six experimental groups (Fig.

6A and B). The control group exhibited a higher relative abundance of Corynebacteriales, Globicatella_stpucanine_oral_taxon_218, Globicatella, and Frankiales. In contrast, the AR group showed increased abundance of Desulfovibrio, unidentified_Rizobiales, Eubacterium_plexicaudatum, and Microscillaceae.

In the Lor group, the predominant taxa included Planctomycetota and Solirubrobacteraceae. The Rg5-L group was characterized by increased abundance of Bacilli, Staphylococcales, and Staphylococcaceae. The Rg5-M group was enriched in Aerococcaceae, Aerococcus, Enterobacterales, and Pasteurellaceae, whereas the Rg5-H group was mainly enriched in Lactobacillales, Streptococcus, and Streptococcaceae.

Fig. 5D shows the detailed information on other dominant species.Fig. 6Analysis of the nasal microbiota LESFE in rats with allergic rhinitis.

(A) Evolutionary branching diagram of differential genus between six group. (B) LDA value distribution histogram between six group. (C) The relationship between nasal microbiota and JAK2/STAT3/BCL-2, MAPK signaling pathways, and cytokines.Fig.

6

Relationship between nasal microbiota and JAK2/STAT3/BCL-2, MAPK signaling pathways, and cytokines

Fig. 6C presents a correlation heatmap illustrating the relationships between microbial species and biochemical indicators. The increased relative abundance of several genera, including Crenarchaeota, Latescibacter, and Sva0485, was positively correlated with elevated levels of IgE, His, and pro-inflammatory factors, as well as with increased activation of signaling pathways such as MAPK, JAK2, and STAT3.

These associations suggest that these taxa may contribute to immunomodulation and the development of inflammation. In contrast, increased abundance of Bdellovibrionota, Patescibacteria, Campylobacter, and Acidobacteriota was associated with significantly decreased levels of anti-inflammatory factors and BCL-2, suggesting immunosuppressive and anti-inflammatory effects. The abundance of Myxococcata and Firmicutes was positively correlated with JAK2 and STAT3 levels.

In contrast, the relative abundance of Caldatribacter was negatively correlated with JAK2 and STAT3, as well as with MAPK pathway activation. Armatimonadota exhibited a positive correlation with anti-inflammatory factors and BCL-2. RCP2.54 and Myxococcata were negatively correlated with anti-inflammatory factors and BCL-2.

Dadabacteria showed a positive correlation with pro-inflammatory factors. Proteobacteria was positively correlated with IgE, His, and other inflammatory markers. WPS.2 and Desulfobacteria were positively correlated with activation of the MAPK signaling pathway.

Bdellovibrionota and Elusimicrobiota showed negative correlations with IgE, His, and pro-inflammatory factors. In contrast, Hadarchaeota displayed a positive correlation with IgE and His indicators and a negative correlation with the MAPK signaling pathway. Correlation analysis between microbial abundance, the JAK2/STAT3/BCL-2 and MAPK signaling pathways, and cytokine levels revealed that modulating the abundance of specific bacterial genera could improve key indicators such as cytokines, IgE, His, and components of the MAPK, JAK2, and STAT3 pathways.

Collectively, these findings indicate a potential for coordinated regulation of microbial communities, biochemical markers, and signaling pathways.

Discussion

AR is a prevalent chronic inflammatory disorder affecting the respiratory tract. Based on differences in allergen properties and immune mechanisms, AR is generally classified into two main experimental models: the classic Th2-mediated model induced by ovalbumin (OVA) and the chemical hapten model induced by TDI [16]. As a classic macromolecular allergen, OVA exhibits distinct immunological characteristics.

During the early IgE-dependent phase, IL-5 secreted by eosinophils/basophils and Th2 cells drives Th cells toward Th2 differentiation. Subsequently, pro-inflammatory cytokines such as IL-4, IL-5, and IL-1β secreted by Th2 cells stimulate B cells to produce IgE. IgE binding to basophils further suppresses Th1 differentiation, ultimately establishing a Th2-dominant immune response that drives AR progression [17].

TDI, as a low-molecular-weight blood antigen and common occupational allergen, can elicit a Th2-type immune response and induce nasal inflammatory characteristics similar to those observed in human AR. Because of its close resemblance to the complex pathological environment of occupational AR, it is increasingly employed to establish experimental AR models [18]. Our findings indicate that TDI-induced AR is predominantly characterized by Th2-dominant immune responses during later stages.

Specifically, IL-4 stimulates IgE production, eosinophil infiltration, and excessive mucus secretion by activating B cells, eosinophils, and epithelial cells, thereby exacerbating chronic inflammation. Recent studies indicate that IL-6, primarily secreted by immune and epithelial cells, modulates Th1/Th2 balance and amplifies inflammatory signals, acting as a key regulatory factor in AR pathogenesis [19]. Under physiological conditions, IL-6 is expressed at low to moderate levels in nasal epithelial cells; however, stimulation with allergen (e.g., TDI) substantially increases IL-6 levels in nasal washings.

IL-6 knockout mice reportedly exhibit reduced Th2 cytokine secretion following allergen sensitization, along with alleviated AR symptoms [20]. Moreover, serum IL-6 levels in patients with AR have been shown to positively correlate with disease severity, and IL-6 genetic polymorphisms are associated with increased susceptibility to AR [21]. Although the precise role of IL-6 dynamics in the nasal mucosal microenvironment during TDI-induced AR remains unclear, our study demonstrated that IL-6 secretion from nasal mucosal cells is markedly elevated in TDI-sensitized rats.

Notably, Rg5 treatment effectively alleviated TDI-induced AR symptoms by inhibiting IL-6 signaling pathways.

Natural products represent a vital resource for drug development owing to their extensive biological activities. Rg5 has been shown to exert anti-inflammatory effects in airway mucosal cells [22] and markedly inhibit IgE–antigen complex–induced passive cutaneous allergic reactions in rats. Rg5 intervention substantially alleviates skin dermatitis in mice by blocking IgE-mediated mast cell degranulation, thereby inhibiting the release of pro-inflammatory mediators including His and leukotrienes [13].

Concurrently, Rg5 reduces pro-inflammatory mediator production via the NF-κB pathway, modulates Th1/Th2 balance, and decreases IgE levels, thereby exerting multi-targeted anti-allergic effects [23]. Although the anti-inflammatory and anti-allergic activities of Rg5 have been reported, its specific role and mechanisms in AR remain elusive. Our study demonstrated that Rg5 effectively alleviated AR symptoms by coordinately regulating the JAK2/STAT3/BCL-2 and MAPK signaling pathways, while modulating the nasal microbiome.

Inflammatory dysregulation and impaired immune homeostasis constitute core mechanisms in allergic diseases, with the JAK/STAT pathway serving as a pivotal cytokine-mediated signaling axis involved in cell proliferation, differentiation, and immunoregulation. JAK2, a non-receptor tyrosine kinase, is widely expressed across tissues. Its p-STAT3 form induces target gene transcription, driving adaptive immune responses [24].

In OVA-induced AR, elevated levels of tumor necrosis factor (TNF)-α and interferon-γ activate JAK2/STAT3, thereby exacerbating nasal mucosal inflammation and inducing epithelial cell apoptosis [25]. Accordingly, we observed that elevated IL-6 and IL-4 levels in TDI-induced AR promote p-STAT3 generation by activating the JAK2-STAT3 axis, consistent with the findings of Zhang et al. (2023) [26].

However, downstream effects of p-STAT3 activation may vary depending on the cellular environment, leading to distinct roles in AR pathogenesis and contributing to inflammatory responses [27]. We further demonstrated that p-STAT3 also regulates the expression of the anti-apoptotic protein BCL-2, suggesting its involvement in both apoptosis regulation and immunomodulation. The MAPK pathway, mediated via ERK, JNK, and p38 kinases, bidirectionally regulates inflammatory cell survival: JNK/p38 activation induces Bim phosphorylation or Bax translocation to mitochondria, promoting apoptosis; meanwhile, ERK activation typically upregulates BCL-2 to maintain cell survival [28,29].

However, our study revealed that p-ERK activation downregulates BCL-2 expression by inducing the pro-apoptotic protein Bim to bind to BCL-2 and inhibit its function [30], thus identifying BCL-2 as a key crossroads node between the JAK2/STAT3 and MAPK pathways. Although interactions between these pathways in diseases such as obesity-associated asthma have been reported [31,32], their synergistic mechanism in AR remains unclear. We demonstrated that the JAK2/STAT3 and MAPK pathways exert a synergistic effect in the pathogenesis of AR.

Following binding of IL-4 and IL-6 to their receptors, the Shc–Grb2–SOS complex may be recruited via the gp130 subunit, thereby initiating the Ras–Raf–MEK–ERK cascade and leading to ERK activation. Activated ERK phosphorylates STAT3 at Ser727, amplifying its activity [32]. In parallel, IL-6 receptor–mediated activation of JAK2 can also directly phosphorylate STAT3, promoting its dimerization and nuclear translocation [33].

Collectively, these mechanisms indicate that the MAPK and JAK2-STAT3 pathways converge via STAT3 and BCL-2, thereby cooperatively regulating pathological processes associated with AR and other inflammatory diseases.

Microbiome dysbiosis substantially promotes the development of AR, with the nasal microbiota serving as a crucial link between environmental exposures and host health. Microbiota can modulate immune responses and microbial composition by influencing intestinal and respiratory lymphocytes and their migration [34]. A decreased abundance of Actinomycetes and an increased abundance of Bacteroidetes in the nasal cavities of patients with AR [35] may contribute to disease mechanisms, as both phyla are crucial for maintaining nasal microbial equilibrium.

AR episodes frequently induce dysbiosis, manifesting as depletion of beneficial bacteria and/or proliferation of potentially harmful bacteria [36]. Although studies have confirmed that Rg5 can modulate gut microbiota [37], its effects on nasal microbiota in AR rats remain unexplored. In the present study, Rg5 treatment enhanced nasal microbial diversity and altered microbial composition in rats, specifically increasing the abundance of Actinobacteriota and Acidobacteriota while decreasing that of Bacteroidota and Desulfobacterota.

Actinobacteriota can strengthen the airway barrier and inhibit pathogenic bacterial growth, potentially alleviating AR symptoms [35]. Acidobacteriota thrive in the acidic nasal environment, aiding homeostasis. In contrast, Bacteroidota produce succinate, which activates mast cells to release His, exacerbating symptoms such as nasal itchiness.

They may also degrade proteins in the mucus layer, facilitating allergen penetration. Overgrowth of Desulfobacterota can generate hydrogen sulfide, damaging the epithelial barrier and enhancing allergen permeability. In addition, it induces oxidative stress in epithelial cells and promotes Th2 responses, thereby aggravating AR symptoms [38].

These compositional shifts in bacterial communities are of considerable importance for restoring the nasal microbiota homeostasis in TDI-induced AR rats. In allergic response models, short-chain fatty acids (e.g., butyrate) produced by Patescibacteria stimulate intestinal epithelial cells, upregulate tight junction proteins (e.g., ZO-1), and reinforce the intestinal barrier. This reduces endotoxin and pathogen permeation, inhibits immunoglobulin and pro-inflammatory cytokine secretion, and ultimately alleviates inflammation [39].

Conversely, Crenarchaeota may induce pro-inflammatory metabolites or disrupt host metabolism, triggering the release of pro-inflammatory cytokines (e.g., IL-6, TNF-α) [40]. To investigate the relationship between nasal microbiota and AR immune signaling, we performed correlation analyses among key nasal bacterial genera, the MAPK signaling pathway, the JAK2/STAT3/BCL-2 signaling pathway, and AR-related biomarkers. We found that increased abundance of taxa such as Crenarchaeota was positively correlated with elevated IgE, His, and pro-inflammatory cytokine levels, as well as with increased activation of key indicators of immune dysregulation and impaired apoptosis (MAPK, JAK2, and STAT3).

In contrast, increased abundance of taxa such as Bdellovibrionota correlated with higher levels of anti-inflammatory cytokines and BCL-2, suggesting potential immunosuppressive and anti-inflammatory effects. Correlation analysis between microbial abundance and signaling pathway activity suggested that changes in specific bacterial genera may be associated with improved cytokine profiles, reduced levels of IgE and His, and activation of the MAPK and JAK2/STAT3/BCL-2 pathway components. These results highlight potential coordinated interactions among the nasal microbiota, immune signaling, and AR-related biochemical mediators.

Our findings underscore the pivotal role of nasal microbial dysbiosis in the pathogenesis of AR and suggest specific bacterial genera as therapeutic targets, consistent with previous studies on the roles of Crenarchaeota and Patescibacteria. Furthermore, Rg5 may exert therapeutic effects in part by modulating the nasal microbiota; however, the precise mechanisms by which other bacterial genera influence AR pathogenesis warrant further investigation.

Conclusion

In summary, our study demonstrated that Rg5 ameliorates AR symptoms in rats, modulates tissue inflammation and immune imbalance, alleviates nasal mucosa and lung tissue damage, and improves the composition and structure of nasal flora. These effects may be mediated through the coordinated regulation of MAPK and JAK2/STAT3/BCL-2 signaling pathways. Therefore, Rg5 may be a promising candidate for the treatment of AR.

Declaration of competing interest

The authors declare no conflicts of interest.

Related articles

PubMed

Licoflavone B mitigates allergic rhinitis by restraining epithelial PI3K-AKT/NF-κB NLRP3 inflammasome signaling.

Allergic rhinitis remains highly prevalent and is often incompletely controlled by current therapies, while accumulating evidence implicates epithelial PI3K–AKT/NF-κB-mediated activation of the NLRP3 inflammasome in upper-airway inflammation. This study investigated whether the licorice-derived flavonoid Licoflavone B (LFB) alleviates allergic rhinitis by modulating this signaling axis. In an ovalbumin-induced murine model, allergic rhinitis-like symptoms and nasal histopathological changes were...

PubMed

Staphylococcus aureus-derived xanthine exacerbates allergic rhinitis-induced olfactory dysfunction through promoting Th17 cell differentiation and IL-17A production.

Abstract Objectives Allergic rhinitis (AR) is frequently accompanied by olfactory dysfunction (OD), yet the role of microbial metabolites in this process remains poorly elucidated. This study aimed to investigate how xanthine, a metabolite derived from Staphylococcus aureus (Sa), exacerbates AR‐induced OD by promoting Th17 cell differentiation and IL‐17A production. Methods Multi‐omics analyses, comprising metabolomics, proteomics and 16S rRNA gene sequencing, were performed on AR patients a...